{"id":"93.365","name":"Sickle Cell Treatment Demonstration Program","popular_name":"SCDTDP","objective":"The objectives of this project is to support the development and establishment of systemic mechanisms to improve the prevention and treatment of sickle cell disease complications, including the coordination of service delivery for individuals with sickle cell disease; genetic counseling and testing; bundling of technical services related to the prevention and treatment of sickle cell disease; training of health professionals; and identifying and establishing efforts related to the expansion and coordination of education, treatment, and continuity of care for individuals with Sickle Cell Disease as authorized in 42 USC Section 300b-5(b) (Section 1106(b) of the Public Health Service Act).","sam_url":"https://sam.gov/fal/fd5a35dafefb4e5ab401b925de637af3/view","usaspending_url":"https://www.usaspending.gov/search/?hash=79fdc4b71e47e45355e12ba2037cc04a","grants_url":"https://grants.gov/search-grants?cfda=93.365","top_agency_name":"Department of Health and Human Services","sub_agency_name":"Health Resources and Services Administration","assistance_types":["Project Grants"],"beneficiary_types":["Health Professional","Physically Afflicted (e.g. TB, Arthritis, Heart Disease)","Public nonprofit institution/organization","Specialized group (e.g. health professionals, students, veterans)"],"applicant_types":["Private nonprofit institution/organization (includes institutions of higher education and hospitals)"],"categories":[],"obligations":[{"x":"2023","sam_estimate":0.0,"sam_actual":5950000.0,"usa_spending_actual":5950000.0},{"x":"2024","sam_estimate":0.0,"sam_actual":5620000.0,"usa_spending_actual":5316009.62},{"x":"2025","sam_estimate":0.0,"sam_actual":5000000.0,"usa_spending_actual":0.0}],"other_program_spending":null,"outlays":[{"x":"2023","outlay":0.0,"obligation":0.0},{"x":"2024","outlay":0.0,"obligation":0.0},{"x":"2025","outlay":0.0,"obligation":0.0}],"results":[{"year":"2020","description":"In FY 20, The Sickle Cell Treatment Demonstration Program served more than 25,000 individuals living with Sickle Cell Disease across the United States."},{"year":"2021","description":"Sickle Cell Treatment Demonstration Program served more than 25,000 individuals living with sickle cell disease(SCD) across the United States. Providers participating in the program prescribed hydroxyurea (a disease-modifying therapy) to 70% of their pediatric population and 14% of their pediatric population with other disease-modifying treatments. 57% of their adult patients received hydroxyurea prescriptions and 33% of their adult patients received other disease modifying therapy prescriptions. Furthermore, SCD providers indicated that 65% of eligible individuals with SCD (ages 2-16) had a transcranial doppler screening within the past 15 months, an important tool for detecting stroke risk which is elevated in individuals with SCD."},{"year":"2022","description":"In FY 20, the Sickle Cell Treatment Demonstration Program served more than 25,000 individuals living with sickle cell disease(SCD) across the United States. Providers participating in the program prescribed hydroxyurea (a disease-modifying therapy) to 70% of their pediatric population and 14% of their pediatric population with other disease-modifying treatments. 57% of their adult patients received hydroxyurea prescriptions and 33% of their adult patients received other disease modifying therapy prescriptions. Furthermore, SCD providers indicated that 65% of eligible individuals with SCD (ages 2-16) had a transcranial doppler screening within the past 15 months, an important tool for detecting stroke risk which is elevated in individuals with SCD."},{"year":"2023","description":"In FY 23, the Sickle Cell Treatment Demonstration Program served more than 25,000 individuals living with sickle cell disease (SCD) across the United States. Providers participating in the program prescribed  disease-modifying therapies to more than 75% of their patient population. Furthermore, almost 3,800 providers participated in SCD-based Project ECHO sessions or telementoring calls, which helps expand the number of providers with improved SCD knowledge and care tools and resources."}],"authorizations":[{"text":"Public Health Service Act, 1106(b). 42 U.S.C. &sect; 300b-5(b).","url":"https://www.govinfo.gov/link/uscode/42/300"}],"program_type":"assistance_listing","is_subpart_f":1,"rules_regulations":"This program is subject to the provisions of 45 CFR Part 92 for State, local and tribal governments and 45 CFR Part 74 for institutions of higher education, hospitals, other nonprofit organizations and commercial organizations, as applicable. HRSA awards are subject to the requirements of the HHS Grants Policy Statement (HHS GPS) that are applicable based on recipient type and purpose of award. The HHS GPS is available at https://www.hhs.gov/sites/default/files/hhs-grants-policy-statement-october-2024.pdf.","improper_payments":[],"gwo":null,"pons":[]}